CN-122012320-A - Application of bacteroides xylanisolvens capable of promoting enterobacteria to produce propionic acid and composition thereof in relieving ulcerative colitis

Abstract

The invention discloses a xylan-like bacteroides capable of promoting enterobacteria to produce propionic acid and application of a composition thereof in relieving ulcerative colitis, and belongs to the technical field of microorganisms. The xylan-mimetic NSP016 can rapidly utilize konjac glucomannan, and the composition of the xylan-mimetic and the konjac glucomannan can improve the histopathological score of ulcerative colitis mice, maintain the integrity of intestinal barriers, reduce the level of oxidative stress, obviously reduce the level of clinical diagnosis markers of colitis, and has better effect than clinical medicine mesalamine. The xylan-mimetic bacillus NSP016 and the composition thereof have very wide application prospects in the aspects of preparing food, pharmaceutical compositions, health-care products or feed additives for relieving ulcerative colitis.

Inventors

• NIE SHAOPING
• TAN HUIZI
• Qin Zuoqi
• Xuan Yiru
• GUAN YUTING

Assignees

• 南昌大学

Dates

Publication Date

20260512

Application Date

20260128

Claims (10)

1. 1. A strain of the xylan-degrading bacteroides (Bacteroides xylanisolvens) NSP016 is preserved in the microorganism strain collection of Guangdong province at the 9 th month 12 days of 2025, and the preservation address is No. 59 building 5 in the martyr th road of Guangzhou city, and the preservation number is GDMCC No:66954.
2. 2. A composition comprising, as a main ingredient, the composition contains the bacteroides xylanisolvens NSP016 and prebiotics according to claim 1; the prebiotic comprises konjak glucomannan.
3. 3. The composition according to claim 2, wherein the number of cells of the Bacteroides xylanisolvens NSP016 is not less than 1X 10 6 CFU/mL or 1X 10 6 CFU/g, the mannose composition in the konjak glucomannan is higher than 50%, and the konjak glucomannan is not less than 0.2% of the total mass of the composition.
4. 4. A product comprising bacteroides xylanisolvens NSP016 according to claim 1 or a composition according to claim 2 or 3.
5. 5. The product of claim 4, wherein the product is a microbial inoculant, a food product, a pharmaceutical composition, a health product, or a feed additive.
6. 6. The product according to claim 4 or 5, wherein the number of cells of bacteroides xylanisolvens NSP016 in the product is not less than 1 x 10 6 CFU/mL or 1 x 10 6 CFU/g.
7. 7. Use of the bacteroides xylanisolvens NSP016 according to claim 1 or the composition according to claim 2 or 3 for the preparation of a medicament or feed additive for the prevention and/or treatment of ulcerative colitis.
8. 8. The use according to claim 7, wherein the pharmaceutical product comprises a dosage form selected from the group consisting of granules, capsules, tablets, pills, and oral liquids.
9. 9. Use of bacteroides xylanisolvens NSP016 according to claim 1 for increasing the effect of konjak glucomannan in improving colitis.
10. 10. Use of bacteroides xylanisolvens NSP016 according to claim 1 for the preparation of propionic acid.

Description

Application of bacteroides xylanisolvens capable of promoting enterobacteria to produce propionic acid and composition thereof in relieving ulcerative colitis Technical Field The invention relates to a xylan-like bacteroides capable of promoting enterobacteria to produce propionic acid and application of a composition thereof in relieving ulcerative colitis, and belongs to the technical field of microorganisms. Background Inflammatory bowel disease (Inflammatory bowel disease, IBD) is a non-specific chronic inflammatory disease of the intestinal tract, which is predominantly affected by the digestive system, and mainly includes both types of crohn's disease and ulcerative colitis. The former damages any gastrointestinal part from the mouth to the anus, most commonly seen with the small intestine end and colon, and the latter damages mainly the colon and rectum. The most prominent symptom of ulcerative colitis is diarrhea, mucopurulent bloody stool. The pathogenesis of the disease is hidden, the clinical manifestations are various and lack of specificity, the etiology is not completely clear at present, the pathogenesis is complex, and the mechanism explanation is not clear, so that the disease brings significant challenges for clinical treatment. The intestinal flora is closely related to ulcerative colitis, and the core mechanism involves intestinal barrier destruction, immune abnormality activation and inflammation reaction aggravation caused by dysbacteriosis. The intestinal flora diversity of ulcerative colitis patients is obviously reduced, beneficial bacteria (such as lactobacillus and bifidobacterium) are reduced, harmful bacteria (such as escherichia coli and clostridium) are increased, and excessive proliferation of partial pathogenic bacteria can trigger inflammatory reaction. Dysbacteriosis destroys the integrity of the intestinal mucosal barrier, resulting in increased permeability, invasion of bacteria and their metabolites into the intestinal wall, activation of the immune system to release inflammatory factors (e.g. TNF- α, IL-6), forming a malignant cycle of "dysbacteriosis-barrier destruction-immune overreaction". The production of flora metabolites, such as short chain fatty acids, is reduced, impairing its anti-inflammatory and mucosal action, while deleterious metabolites (such as pro-inflammatory substances) accumulate, further exacerbating intestinal inflammation. At present, flora intervention, such as probiotics, prebiotics, faecal fungus transplantation and the like, have become potential treatment strategies for ulcerative colitis, and intestinal barrier function and immune status can be improved by restoring flora balance. The UC symptoms can be prevented and treated by supplementing specific dietary fibers (such as fructo-oligosaccharide and inulin) or directly supplementing beneficial living bacteria (such as certain lactobacillus and bifidobacterium strains), the dietary fibers are taken as substrates available for intestinal flora and degraded by the beneficial bacteria, so that the production of short-chain fatty acids is promoted, the high antioxidant activity is exerted, and the colonization of pathogens in intestinal tracts is inhibited. The bacteroides is the bacterium with the highest content in the human intestinal symbiotic bacteria, and has close connection with the immune, metabolic and nervous systems of hosts. There have been studies on the possibility that bacteroides are "new generation probiotics". For example, patent CN114933993a discloses that a strain of bacteroides xylanisolvens (Bacteroides xylanisolvens) NSP003 and its complex preparation with pectin can exert a relief effect on ulcerative colitis mice by reducing disease activity index, maintaining intestinal barrier and the like. Besides pectin, other dietary fibers such as konjak glucomannan, inulin, beta-glucan and the like can relieve intestinal inflammation by relieving colonic atrophy, enhancing intestinal barrier, reducing oxidative stress level, maintaining intestinal microecological balance and the like, and whether probiotics and other dietary fibers can act synergistically to the ulcerative colitis to play an intervention role is worth further exploration, and a new thought can be provided for the development of foods, pharmaceutical compositions, health care products or feed additives for relieving the ulcerative colitis. Disclosure of Invention According to the experiment, a large amount of experimental researches are carried out, the konjak glucomannan can be rapidly degraded, the xylan-induced bacteroides can relieve ulcerative colitis, and the strain and the combination of the strain and the konjak glucomannan can improve the symptoms of disease activity index rise, spleen swelling and the like of ulcerative colitis mice in an animal model, can maintain the integrity of intestinal barriers of the mice, reduce the level of oxidative stress and relieve the oxidative damage of systemic and or